Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study.

Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S.

J Affect Disord. 2012 Dec 10;141(2-3):308-14. doi: 10.1016/j.jad.2012.03.033. Epub 2012 Apr 18.

PMID:
22516310
2.

Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.

Lin CH, Lin SH, Jang FL.

J Clin Psychopharmacol. 2011 Oct;31(5):563-8. doi: 10.1097/JCP.0b013e31822bb0db.

PMID:
21869699
3.
4.

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M.

Mol Psychiatry. 2006 Jul;11(7):680-4. Epub 2006 Feb 21.

PMID:
16491133
5.

Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression--no influence of celecoxib treatment.

Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Müller N.

J Affect Disord. 2011 Nov;134(1-3):217-25. doi: 10.1016/j.jad.2011.05.047. Epub 2011 Jun 17.

PMID:
21684012
6.

Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.

Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A.

Depress Anxiety. 2009;26(7):607-11. doi: 10.1002/da.20589.

PMID:
19496103
7.

BDNF, interleukin-6, and salivary cortisol levels in depressed patients treated with desvenlafaxine.

Ninan PT, Shelton RC, Bao W, Guico-Pabia CJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:86-91. doi: 10.1016/j.pnpbp.2013.09.016. Epub 2013 Oct 2.

PMID:
24096053
8.
9.

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

Trivedi MH, Pigotti TA, Perera P, Dillingham KE, Carfagno ML, Pitts CD.

J Clin Psychiatry. 2004 Oct;65(10):1356-64.

PMID:
15491239
10.

Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.

Na KS, Lee KJ, Lee JS, Cho YS, Jung HY.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:79-85. doi: 10.1016/j.pnpbp.2013.09.006. Epub 2013 Sep 20. Erratum in: Prog Neuropsychopharmacol Biol Psychiatry. 2016 Apr 3;66:136.

PMID:
24056287
11.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
12.

Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.

Cooper-Kazaz R, Apter JT, Cohen R, Karagichev L, Muhammed-Moussa S, Grupper D, Drori T, Newman ME, Sackeim HA, Glaser B, Lerer B.

Arch Gen Psychiatry. 2007 Jun;64(6):679-88.

PMID:
17548749
13.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
14.

A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.

Munizza C, Olivieri L, Di Loreto G, Dionisio P.

Curr Med Res Opin. 2006 Sep;22(9):1703-13.

PMID:
16968574
15.
16.
17.

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM.

J Clin Psychopharmacol. 2008 Apr;28(2):156-65. doi: 10.1097/JCP.0b013e31816774f9.

PMID:
18344725
18.

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, Metz A.

J Clin Psychiatry. 2001 Oct;62(10):776-81.

PMID:
11816866
19.

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.

Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. doi: 10.1097/YIC.0b013e32833a86aa.

PMID:
20856123
20.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295

Supplemental Content

Support Center